# Verismo Therapeutics Presents Preclinical Data at SITC 2026 Demonstrating Enhanced Tumor Control and Reduced Cytokine Release with SynKIR™-110 KIR-CAR Compared to Conventional CAR T

- Source: PR Newswire M&A
- Published: 2026-11-04T00:00:00+00:00
- Category: Business
- Original: https://www.prnewswire.com/news-releases/verismo-therapeutics-presents-preclinical-data-at-sitc-2026-demonstrating-enhanced-tumor-control-and-reduced-cytokine-release-with-synkir-110-kir-car-compared-to-conventional-car-t-302927546.html
- Canonical: https://groundlevelnews.com/story/verismo-therapeutics-presents-preclinical-data-at-sitc-2026-demonstrat-9fd3d5/

SynKIR™-110 demonstrated faster tumor control with approximately 10-fold lower IFNγ and 30-fold lower TNFα and IL-2 production compared to CD28-based single-chain CAR T in preclinical models Preclinical in vivo data showed reduced exhaustion of tumor-infiltrating SynKIR™-110 T cells and...

_Ground Level News shows a short summary only; the full article and all rights belong to PR Newswire M&A._